BELESALA
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

BELESALA Trademark

Serial Number: 79273317 • Registration: 6182097

BELESALA is a trademark filed by Mallinckrodt Pharmaceuticals Ireland Limited on September 10, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Mallinckrodt Pharmaceuticals Ireland Limited (7 trademarks)

College Business & Technology Park
Blanchardstown, Dublin 15 D15 TX2V , IE

Entity Type: 77

Trademark Details

Filing Date

September 10, 2019

Registration Date

October 27, 2020

Published for Opposition

August 11, 2020

Goods & Services

Medical apparatus and instruments for use in connection with the administration of gases to patients for medical and therapeutic purposes and accessories and parts thereof, namely, medical and therapeutic gas delivery systems comprised primarily of gas cylinders, valves, regulators, flow meters, delivery hoses and apparatus and instruments for setting, measuring and regulating the mixture of medical and therapeutic gases delivered to patients; therapeutic medical device and accessories and parts thereof for extracting blood from the body, separating blood, treating it extracorporally, and returning it to the body used for extracorporeal photopheresis, extracorporeal photo immune therapy, extracorporeal photo chemotherapy, and cellular therapies; medical device, namely, medical syringes used for manual injection

Pharmaceutical preparations for the treatment of neurological diseases and disorders, nephrotic diseases, endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases and disorders, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous state, gastrointestinal diseases, hepatic diseases and disorders, biliary diseases and disorders, renal disorders, cardiovascular and lipid-related diseases and disorders, inflammatory and autoimmune diseases and disorders; intravenous analgesics and antipyretics; syringes sold prefilled with pharmaceutical preparations for the treatment of neurological diseases and disorders, nephrotic diseases, endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases and disorders, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous state, gastrointestinal diseases, hepatic diseases and disorders, biliary diseases and disorders, renal disorders, cardiovascular and lipid-related diseases and disorders, inflammatory and autoimmune diseases and disorders, and intravenous analgesics and antipyretics

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Jun 4, 2026 NREP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 13, 2026 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 13, 2026 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 13, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 13, 2026 REAP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Oct 27, 2025 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Jan 21, 2024 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 4, 2021 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Feb 11, 2021 XXSS
GENERIC MADRID TRANSACTION CREATED
Feb 11, 2021 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 27, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Oct 27, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 11, 2020 NPUB
PUBLISHED FOR OPPOSITION
Aug 11, 2020 PUBO
NOTIFICATION PROCESSED BY IB
Aug 7, 2020 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 22, 2020 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jul 22, 2020 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 22, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 7, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 7, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 7, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 7, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 7, 2020 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 6, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 6, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 6, 2020 TROA
REFUSAL PROCESSED BY IB
Feb 8, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 21, 2020 RFCS
REFUSAL PROCESSED BY MPU
Jan 21, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 12, 2019 RFCR
NON-FINAL ACTION WRITTEN
Dec 11, 2019 CNRT
ASSIGNED TO EXAMINER
Dec 11, 2019 DOCK
APPLICATION FILING RECEIPT MAILED
Dec 10, 2019 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 6, 2019 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 5, 2019 REPR